Cargando…
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663819/ https://www.ncbi.nlm.nih.gov/pubmed/33167404 http://dx.doi.org/10.3390/ijms21218288 |
_version_ | 1783609715619528704 |
---|---|
author | Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez-Larrea, Salomé Keszenman, Deborah J. Lafon-Hughes, Laura |
author_facet | Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez-Larrea, Salomé Keszenman, Deborah J. Lafon-Hughes, Laura |
author_sort | Perini, Valentina |
collection | PubMed |
description | Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested. |
format | Online Article Text |
id | pubmed-7663819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76638192020-11-14 PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez-Larrea, Salomé Keszenman, Deborah J. Lafon-Hughes, Laura Int J Mol Sci Article Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested. MDPI 2020-11-05 /pmc/articles/PMC7663819/ /pubmed/33167404 http://dx.doi.org/10.3390/ijms21218288 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez-Larrea, Salomé Keszenman, Deborah J. Lafon-Hughes, Laura PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title | PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_full | PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_fullStr | PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_full_unstemmed | PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_short | PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_sort | parp inhibitor olaparib causes no potentiation of the bleomycin effect in vero cells, even in the presence of pooled atm, dna-pk, and ligiv inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663819/ https://www.ncbi.nlm.nih.gov/pubmed/33167404 http://dx.doi.org/10.3390/ijms21218288 |
work_keys_str_mv | AT perinivalentina parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors AT schackemichelle parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors AT liddlepablo parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors AT vilchezlarreasalome parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors AT keszenmandeborahj parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors AT lafonhugheslaura parpinhibitorolaparibcausesnopotentiationofthebleomycineffectinverocellseveninthepresenceofpooledatmdnapkandligivinhibitors |